The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study.

Takeda, Yuichiro; Kusaba, Yusaku; Tsukita, Yoko; Uemura, Yukari; Miyauchi, Eisaku; Yamamoto, Takaya; Mayahara, Hiroshi; Hata, Akito; Nakayama, Hidetsugu; Tanaka, Satoshi; Uchida, Junji; Usui, Kazuhiro; Toyoda, Tatsuya; Tamiya, Motohiro; Morimoto, Masahiro; Oya, Yuko; Kodaira, Takeshi; Jingu, Keiichi; Sugiura, Hisatoshi

Takeda, Yuichiro; Kusaba, Yusaku; Tsukita, Yoko; Uemura, Yukari; Miyauchi, Eisaku; Yamamoto, Takaya; Mayahara, Hiroshi; Hata, Akito; Nakayama, Hidetsugu; Tanaka, Satoshi; Uchida, Junji; Usui, Kazuhiro; Toyoda, Tatsuya; Tamiya, Motohiro; Morimoto, Masahiro; Oya, Yuko; Kodaira, Takeshi; Jingu, Keiichi; Sugiura, Hisatoshi.

Afiliación

Takeda Y; Department of Respiratory Medicine, National Center for Global Health and Medicine, 1-21-1 Toyama Shinjuku-ku, Tokyo 162-8655, Japan.
Kusaba Y; Department of Respiratory Medicine, National Center for Global Health and Medicine, 1-21-1 Toyama Shinjuku-ku, Tokyo 162-8655, Japan.
Tsukita Y; Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-Ku, Sendai 980-8574, Japan.
Uemura Y; Section of Biostatistics, Department of Clinical Research Center, National Center for Global Health and Medicine, 1-21-1 Toyama Shinjuku-ku, Tokyo 162-8655, Japan.
Miyauchi E; Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-Ku, Sendai 980-8574, Japan.
Yamamoto T; Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-Ku, Sendai 980-8574, Japan.
Mayahara H; Department of Radiation Oncology, Kobe Minimally Invasive Cancer Center, 8-5-1, Minatojimanakamachi, Chuo-ku, Kobe, Hyogo 650-0046, Japan.
Hata A; Department of Respiratory Medical Oncology, Kobe Minimally Invasive Cancer Center, 8-5-1, Minatojimanakamachi, Chuo-ku, Kobe, Hyogo 650-0046, Japan.
Nakayama H; Department of Radiation Oncology, National Center for Global Health and Medicine, 1-21-1 Toyama Shinjuku-ku, Tokyo 162-8655, Japan.
Tanaka S; Department of Respiratory Medicine, Osaka General Medical Center, 3-1-56, Bandaihigashi, Sumiyoshi-Ku, Osaka 558-0056, Japan.
Uchida J; Department of Respiratory Medicine, Osaka General Medical Center, 3-1-56, Bandaihigashi, Sumiyoshi-Ku, Osaka 558-0056, Japan.
Usui K; Division of Respirology, NTT Medical Center Tokyo, 5-9-22, Higashigotanda, Shinagawa, Tokyo 141-8625, Japan.
Toyoda T; Department of Radiology, NTT Medical Center Tokyo, 5-9-22, Higashigotanda, Shinagawa, Tokyo 141-8625, Japan.
Tamiya M; Department of Thoracic Oncology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka 541-8567, Japan.
Morimoto M; Department of Radiation Oncology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka 541-8567, Japan.
Oya Y; Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya 464-8681, Japan.
Kodaira T; Department of Radiation Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya 464-8681, Japan.
Jingu K; Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-Ku, Sendai 980-8574, Japan.
Sugiura H; Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-Ku, Sendai 980-8574, Japan.

Clin Transl Radiat Oncol ; 37: 57-63, 2022 Nov.

Article en En | MEDLINE | ID: mdl-36065360

Palabras clave

3D-CRT, 3-dimensional conformal radiation therapy; 95% CI, 95% confidence interval; AE, adverse event; AIC, Akaike's information criterion; CCRT, concurrent chemoradiotherapy; Concurrent chemoradiotherapy; Durvalumab consolidation; FEV1, forced expiratory volume in 1 second; HR, hazard ratio; IMRT, intensity-modulated radiotherapy; IO, immune-oncology; Intensity-modulated radiotherapy; Landmark analysis; Multivariate analysis; NSCLC, non-small-cell lung cancer; Non-small cell lung cancer; OR, odds ratio; OS, overall survival; PFS, progression-free survival; PS, performance status; RECIST, Response Evaluation Criteria in Solid Tumors; ROC, receiver operating characteristic; irAE, immune-related adverse event

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Clin Transl Radiat Oncol Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google